SIWA THERAPEUTICS – We Founded SIWA, Drawing Upon An Understanding Of Aging And The AGEs, To Combat Cancer
SIWA Therapeutics, Inc. has developed 318H, a monoclonal antibody that we believe can become a broadly effective cancer immunotherapeutic. Most recently, we showed that 318H enabled complete remission of pancreatic cancer in vivo in humanized mice – we hope to file an IND application for pancreatic cancer next year. Our founder/CEO, Lewis Gruber, focused on […]